Naratriptan

CNS Drugs

Volumn 8, Issue 5, 1997, Pages 402-408

  Gunasekara, Nishan S ^a   Wiseman, Lynda R ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NARATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D RECEPTOR; SUMATRIPTAN;

CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; FATIGUE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PHOTOPHOBIA; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0030727512     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708050-00006     Document Type: Review

References (24)

1. Lance JW. Current concepts of migraine pathogenesis. Neurology 1993 Jun; 43 Suppl. 3: S11-5
2. Connor HE, Feniuk W, Beattie DT, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997 Ma: 17: 145-52
3. Swan L, Birnie DH, Hood S, et al. The effects of subcutaneous naratriptan 1.5 mg on the systemic, pulmonary, and coronary circulation in patients with suspected coronary artery disease[abstract]. Cephalalgia 1997 May; 17: 428
4. Camici P, Melin J, Gnecchi-Ruscone T, et al. A study of the effect of subcutaneous naratriptan 1.5 mg on mvocardial perfusion in migraineurs using positron emission tomography [abstract]. Cephalalgia 1997 May; 17: 424
5. Camici PG, Melin J, Gnecchi-Ruscone T, et al. A study of the effects of subcutaneous naruuiptan 1.5mg on myocardial perfusion in migraineurs using positron emission tomography. 8th Congress of the International Headache Society: 1997 Jun 10-14; Amsterdam
6. Yogendran L, Boswell D, Winter P, et al. Subcutaneous naratriptan (1mg, 5mg and 10mg) has no effect on peripheral blood How as measured by forearm blood How [abstract]. Cephalalgia 1997 May; 17: 425
7. Kempsford RD, Hoke JF, Huffman CS. The safety, tolerahility and pharmacokinetics of oral naratriplan in healthy subjects [abstract] Cephalalgia 1997 May; 17: 416-7
8. 1-receptor agonist for the treatment of migraine [abstract]. Br J Clin Pharmacol 1993 Aug; 36: 170
9. Mathew NT, Peykamian M, Laurenza A, et al. Efficacy and tolerability of naratriptan tablets in the treatment of migraine: results of a double-blind, placebo-controlled. crossover trial [abstract]. Cephalalgia 1997 May; 17: 418
10. (1B/1D) receptor in cat |abstract| Cephulalgia 1997 May; 17: 403
11. Kempsford RD, Bailie R Fuseau F. Oral naratriptan tablets (2.5-10mg) exhibit dose-proportional pharmacokinelics [abstract]. Cephalalgie 1997 May; 17: 408
12. Fuseau H, Baille P, Kempsford RD. A study to determine the absolute oral bioavailabilily of naratriptan [abstract]. Cephalalgia 1997 May; 17: 417
13. Kempsford R. Clinical pharmacology and pharmacokinetics of naratriptan. Cephalagia 1997; 17: 472-3
14. Kempsford RD, Fuseau E, Snell P, et al. Oral naratriptan pharmacokinetics are predictable in subjects with impaired renal function [abstract] Ophalalgia 1997 May; 17: 408-9
15. Fuseau E, Kempsford RD, Moss J. The pharmacokinetics of oran naratriptan in subjects with impaired hepatic function [abstract]. Cephalalgia 1997 May; 17: 409
16. Kempsford RD, Nichulls B, Lam R, et al. A study to investigate the potential interaction of naratriptan and ergotamme [abstract]. Ccphalalgin 1997 May; 17: 416
17. Kempsford RD, Nicholls B, Lam R, et al. A study to investigate the potential interaction of naratriptan and dihydroergotamine [abstract] Cephalalgia 1997 May; 17: 416
18. Williams P, Kempsford R, Fuseau E, et al. Absence of significant pharmacodynamic or pharmacokinelic interaction with naratriptan and sumatriptan co-administration [abstract]. Cephalalgia 1997 May; 17: 417
19. Klassen A, Webster C, Laurenza A, et al. Naratriptan tablets are effective and well tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled, parallel-group trial. Presented at the American Academy of Neurology, 49th Annual Meeting; 1997 Apr 12-19; Boston
20. Mathew T, Peykamian M, Laurenza A, et al. Efficacy and tolerability of naratriptan tablets in the treatment of migraine: results of a double-blind, placebo-controlled, crossover trial. Presented at the American Academy of Neurology, 49th Annual Meeting; 1997 Apr 12-19; Boston
21. Dahlof C, Winter P, Whitehouse H, et al. Randomized. double-blind, placebo-controlled comparison of oral naratriptan and oral sumatriptan in the acute treatment of migraine. Presented at the American Academy of Neurolgy, 49th Annual Meeting; 1997 Apr 12-19; Boston
22. Göbel H, Boswell D, Winter P, et al. A comparison of the efficacy, safety and tolerability of naratriptan and sumatriptan [abstract]. Cephalalgia 1997 May; 17: 426
23. Bomhof M, Enahoro H, Winter P, et al. Tolerability and efficacy of oral naratriptan 2.5 mg in the acute treatment of migraine over a six-month period [abstract]. Cephalalgia 1997 May: 17:424
24. Gobel H, Boswell D, Winter P, et al. A comparison of the efficacy and tolerability of naratriptan and sumatriptan among migraineurs with a history of frequent (≥50% of attacks) headache recurrence. 8th Congress of the International Headache Society: 1997 Jun 10-14; Amsterdam